Tamargo Juan, Caballero Ricardo, Delpón Eva
Department of Pharmacology, School of Medicine, Universidad Complutense, 28040 Madrid, Spain.
Expert Rev Cardiovasc Ther. 2011 Jul;9(7):815-27. doi: 10.1586/erc.11.91.
Ranolazine is an agent approved for the symptomatic treatment of chronic stable angina that inhibits the late inward sodium current (I(NaL)). I(NaL) amplitude is increased under several pathological conditions, including increased oxidative stress, myocardial ischemia, cardiac hypertrophy, heart failure, long-QT syndrome variant 3 and atrial fibrillation. Experimental and preliminary clinical evidence suggests that ranolazine may represent a new therapeutic strategy in the treatment of a broad spectrum of cardiac arrhythmias. This article reviews the role of the I(NaL) and provides an update on experimental and clinical evidence supporting the efficacy and safety of ranolazine across a broad spectrum of arrhythmias.
雷诺嗪是一种被批准用于慢性稳定型心绞痛症状性治疗的药物，它可抑制晚钠内向电流（I(NaL)）。在多种病理状况下，包括氧化应激增加、心肌缺血、心脏肥大、心力衰竭、长QT综合征3型及心房颤动，I(NaL)的幅度会增加。实验和初步临床证据表明，雷诺嗪可能代表了一种治疗广泛类型心律失常的新治疗策略。本文综述了I(NaL)的作用，并提供了关于支持雷诺嗪在广泛心律失常中疗效和安全性的实验及临床证据的最新情况。
